|
Colorectal Neoplasms
|
0.600 |
GeneticVariation
|
group |
LHGDN |
Thymidylate synthase polymorphism and microsatellite instability: association in colorectal cancer.
|
15571262 |
2004 |
|
Colorectal Neoplasms
|
0.600 |
GeneticVariation
|
group |
LHGDN |
Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene.
|
14760062 |
2004 |
|
Colorectal Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
[Thymidylate synthase and dihydropyrimidine dehydrogenase gene expressions in colorectal cancer using the Danenberg tumor profile method].
|
15222106 |
2004 |
|
Colorectal Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients.
|
15386371 |
2004 |
|
Colorectal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
In this study, we investigated the association between both DPD and TS expressions in primary colorectal tumor and the antitumor effect in patients with metastatic colorectal cancer when treated with a fluoropyrimidine-based protocol.
|
12576451 |
2003 |
|
Colorectal Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
DPD and TS expressions were measured by reverse transcription-PCR in surgically resected materials of primary colorectal tumors from 37 patients who went on to receive oral treatment of uracil and tegafur and leucovorin for either synchronous or metachronous metastatic diseases.
|
12576451 |
2003 |
|
Colorectal Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed.
|
12576452 |
2003 |
|
Colorectal Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
|
14519634 |
2003 |
|
Colorectal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Studies thus far involving colorectal tumors obtained from patients have focused predominantly on the predictive value of levels of TS expression and p53 mutations in determining response to 5-FU.
|
12084458 |
2002 |
|
Colorectal Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Mutations were detected at positions 961 and/or 1031 in the 3'-untranslated regions of the TS gene from the metastases; mutations at these sites were also detected in DNA isolated from normal colon mucosa (n=4) and primary colorectal tumors (n=4).
|
11686531 |
2001 |
|
Colorectal Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
In 44/45 microdissected tumors the TS enhancer genotype was identical between paired samples of colorectal tumor and normal tissue.
|
11445856 |
2001 |
|
Colorectal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Marked variation of thymidylate synthase and folylpolyglutamate synthetase gene expression in human colorectal tumors.
|
10821538 |
1999 |
|
Colorectal Neoplasms
|
0.600 |
Biomarker
|
group |
RGD |
Correlation between histological differentiation and DNA-synthesizing enzymes in rat colorectal tumors induced with 1, 2-dimethylhydrazine.
|
10523711 |
1999 |
|
Colorectal Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
This trial demonstrated that intratumoral TS/beta-actin messenger RNA (mRNA) ratio can accurately predict which metastatic colorectal tumors will be resistant to a leucovorin-modulated 5-FU infusion and which have a high likelihood of responding to such a regimen.
|
9726090 |
1998 |
|
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Nitroglycerin Enhances Cisplatin-Induced Cytotoxicity via AKT Inactivation and Thymidylate Synthase Downregulation in Human Lung Cancer Cells.
|
31630149 |
2020 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Associations between clinical-pathological parameters and biomarkers, HER-2, TYMS, RRMI, and 21-gene recurrence score in breast cancer.
|
31551176 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In patient tissues, TS levels were found significantly higher in poorly differentiated and in triple negative BC, and strongly correlated with worse prognosis.
|
30737477 |
2019 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
The AUC of TYMS for predicting the efficacy of chemotherapy on colon cancer was 0.831 (95% CI, 0.735-0.926), and both had higher predictive values.
|
31423175 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Floxuridine (5'-fluorodeoxyuridine, FUdR) acts as an inhibitor of DNA replication by binding to thymidylate synthase and is widely used to treat colorectal cancer.
|
30611569 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer.
|
31367274 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression.
|
30728402 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Melatonin may serve as a potential therapeutic option on its own, or in conjunction with 5-FU, in the treatment of patients with advanced or chemoresistant CRC.Melatonin inhibits the growth of 5-FU resistant colorectal cancer (CRC) cells through upregulation of miR-215-5p and a concomitant downregulation of TYMS.
|
30590435 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
There was no correlation between ERCC1 mRNA expression, TYMS mRNA and clinicopathological features of colorectal cancer (P>0.05).
|
31423175 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tacalcitol increases the sensitivity of colorectal cancer cells to 5-fluorouracil by downregulating the thymidylate synthase.
|
30923017 |
2019 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
A novel intraperitoneal therapy for gastric cancer with DFP-10825, a unique RNAi therapeutic targeting thymidylate synthase, in a peritoneally disseminated xenograft model.
|
31609087 |
2019 |